CAR-T cell treatment for newly diagnosed high-risk myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 1 study tests a “fully human” CAR-T treatment that targets BCMA to treat newly diagnosed high-risk multiple myeloma. It’s designed to see how well it works and whether it’s safe for people who meet specific blood, heart, infection, and cancer-safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 70 and willing to join the study.
- Your multiple myeloma is newly diagnosed and high-risk (R-ISS stage 3 and “double-hit” or “triple-hit” on a special genetics test).
- You have measurable signs of myeloma on screening (from blood/urine protein tests or bone marrow testing).
- Your overall health score is 0–1 (you’re not severely limited day to day).
- Your blood counts and organ function meet study lab minimums (including kidney, liver, clotting, and enough oxygen levels).
- You can safely avoid pregnancy during the study and for 1 year after CAR-T treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This Phase 1/2 study tests a BCMA-targeting CAR-T cell therapy for people with relapsed or refractory multiple myeloma or related plasma cell diseases. It may help by using your own immune cells, engineered to recognize a specific target on cancer cells.
This trial tests a new immunotherapy called BCMA CAR-T for people with multiple myeloma that is considered high-risk. It aims to see if this treatment can help patients who had a short response to initial therapy or have specific genetic changes in their cancer.
This study tests a new CAR-T cell therapy that targets a protein called BCMA on myeloma cells. It is for patients with newly diagnosed multiple myeloma who cannot have a standard stem cell transplant. The therapy is a one-time infusion of your own immune cells that are modified to attack the cancer.
This Phase 1 study tests an experimental CAR T-cell treatment that targets BCMA in people with relapsed or refractory multiple myeloma. It may help shrink the cancer after it has not responded to several prior therapies.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.